A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia

Completed

Conditions studied: Achondroplasia

In brief

This is a long-term, multi-center, longitudinal, observational study in children with achondroplasia (ACH). The aim is to study height velocity and comorbidities in children with ACH. This is a natural history study and no study medication will be administered.

Key facts

Study ID

NCT03875534

Run by

Ascendis Pharma A/S

People needed

260

Starts

2019-06-19

Expected to finish

2024-01-12

Last updated by the study team

2024-03-19

Who can join

Age: any, up to 8. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Legally authorized representative is willing and able to provide written, signed informed consent (with a written assent from the child when appropriate per local requirements)
• Willing and able to comply with study protocol per investigator judgement
• Clinical diagnosis of achondroplasia (confirmed by the investigator)
• Age between 0 to 8 years old at enrollment
• Able to stand without assistance (if the child is 24 months or older)

You may not qualify if…

• Have received chronic treatment (> 3 months) of human growth hormone (hGH) or other medicinal products intended to affect stature or body proportionality at any time
• Have received any dose of medicinal products intended to affect stature or body proportionality within the previous 6 months of screening
• Have received any investigational medicinal product or device intended to affect stature or body proportionality at any time
• History or presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones
• History of any bone-related surgery that affects growth potential of long bones, such as orthopedic reconstructive surgery and osteotomy (foramen magnum decompression, and laminectomy with full recovery are allowed with minimum of 6 months of bone healing. Limb-lengthening with full recovery is allowed with a minimum of 12 months of bone healing.)
• Have forms of skeletal dysplasias other than achondroplasia or medical conditions that result in short stature or abnormal bone growth [such as severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), hypochondroplasia, growth hormone deficiency, Turner syndrome, pseudoachondroplasia. uncontrolled hypothyroidism, uncontrolled diabetes mellitus, autoimmune disease requiring corticosteroid therapy, inflammatory bowel disease, and chronic renal insufficiency]
• History or presence of malignant disease, other than basal cell epithelioma/carcinoma or completely resected squamous skin cancer with no recurrence for 12 months per medical records

Where it is running

• Ascendis Pharma Investigational Site — Little Rock, Arkansas, United States
• Ascendis Pharma Investigational Site — Oakland, California, United States
• Ascendis Pharma Investigational Site — Aurora, Colorado, United States
• Ascendis Pharma Investigational Site — Wilmington, Delaware, United States
• Ascendis Pharma Investigational Site — Saint Paul, Minnesota, United States
• Ascendis Pharma Investigational Site — Columbia, Missouri, United States
• Ascendis Pharma Investigational Site — Buffalo, New York, United States
• Ascendis Pharma Investigational Site — Houston, Texas, United States
• Ascendis Pharma Investigational Site — Seattle, Washington, United States
• Ascendis Pharma Investigational Site — Madison, Wisconsin, United States
• Ascendis Pharma Investigational Site — Parkville, Victoria, Australia
• Ascendis Pharma Investigational Site — Linz, Austria
• Ascendis Pharma Investigational Site — Edmonton, Alberta, Canada
• Ascendis Pharma Investigational Site — Ottawa, Ontario, Canada
• Ascendis Pharma Investigational Site — Montreal, Quebec, Canada
• Ascendis Pharma Investigational Site — Beijing, China
• Ascendis Pharma Investigational Site — Guangzhou, China
• Ascendis Pharma Investigational Site — Hangzhou, China
• Ascendis Pharma Investigational Site — Shanghai, China
• Ascendis Pharma Investigational Site — Shenzhen, China
• Ascendis Pharma Investigational Site — Wuhan, China
• Ascendis Pharma Investigational Site — Copenhagen, Capital Region, Denmark
• Ascendis Pharma Investigational Site — Paris, France
• Ascendis Pharma Investigational Site — Berlin, Germany
• Ascendis Pharma Investigational Site — Dublin, Ireland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.